scholarly journals Ductal Carcinoma In situ of the Male Breast

Breast Care ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. 288-290 ◽  
Author(s):  
Melissa Brents ◽  
John Hancock
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Nipple Discharge ◽  
Left Breast ◽  
Male Breast ◽  
High Grade

Background: Ductal carcinoma in situ of the male breast is an unusual lesion and most often associated with invasive carcinoma. On rare occasions when the in situ component is present in pure form, histological grade is almost always low to intermediate. Imaging for these patients is difficult as gynecomastia is often present and can mask underlying calcifications or carcinoma. Case Report: We report a case of pure high-grade ductal carcinoma in situ of the male breast in a patient with clear nipple discharge. Breast mammography showed bilateral gynecomastia and benign calcifications. Subsequent breast ultrasound showed dilated ducts of the left breast, and a left breast ductogram showed filling defects suggestive of a papilloma. Excisional biopsy and subsequent mastectomy were consistent with high-grade ductal carcinoma in situ. Conclusion: Male breast cancer is uncommon and, although there is increasing awareness, it is less studied compared to female breast cancer. With a clinical history of nipple discharge of any kind, further evaluation with imaging should be considered. In males with gynecomastia, it is important to remember that ductal carcinoma in situ, even of high grade, is difficult to detect on mammography and may not be associated with suspicious calcifications.

scholarly journals Croatia’s First Experiences in Cytological Diagnosis of High-Grade Ductal Carcinoma in Situ of the Breast: Case Reports and a Review of Literature

2021 ◽  
Vol 6 (6) ◽  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Case Reports ◽  
Nipple Discharge ◽  
Left Breast ◽  
Cytological Diagnosis ◽  
High Grade ◽  
Morphological Criteria

Cases here presented are also first Croatia’s experiences in the cytological diagnosis of breast ductal carcinoma in situ (DCIS). The first patient was a 64-year-old woman, by imaging methods with a wide area of suspect microcalcifications in the left breast lower medial quadrant and abundant, dense, yellow-greyish discharge of the same mammilla and second was a 65-year-old woman with an equivocal lesion in left breast lower lateral quadrant. Morphological findings of both aspirates and nipple discharge from the first patient were practically the same - moderately to highly cellular, with 3D solid aggregates, monolayer sheets and many scattered single clearly malignant cells of large - mainly >5x the diameter of an erythrocyte, round-to-ovaloid, manifestly irregular nuclei, dark blue, polymorphous, often multiple (macro)nucleoli, irregular nuclear outlines and dense, more basophilic, mostly scant cytoplasms arranged in syncytium–like structures. “Dirty” background was overfull of comedo necrosis and dark grayish, sharp, irregular microcalcifications. Cytological diagnosis in both cases was DCIS, high-grade, comedo type. Histopathologically first tumor was big, 6 cm large, estimated as comedo carcinoma with microinvasion focuses not bigger than 1 mm, but without signs of angioinvasion, while the second tumor was smaller, 0.6 cm with wide ducts fully with large polymorphic malignant epithelial cells, central comedo necrosis, cancerisation of some lobules but with the intact basement membrane. It was pure high-grade DCIS, comedo type. Presented cases completely reflect to date knowledge about cytological diagnostic of high-grade DCIS; include necessary morphological criteria - highgrade nuclear atypia, an abundance of comedo necrosis and microcalcifications, confirm our limitation in the presumption of invasion status with large lesion extent, but also prove that cytology is the unquestionably reliable in breast morphological diagnostic, even in such sophisticated and demanding pathological issue like DCIS.

scholarly journals Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?

2019 ◽  
Vol 26 (2) ◽  
pp. 665-671 ◽  
Author(s):  
Gábor Cserni ◽  
Anita Sejben
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Lower Risk ◽  
Carcinoma In Situ ◽  
Randomized Clinical Trials ◽  
Ductal Carcinoma ◽  
High Grade

AbstractDuctal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

scholarly journals Metastatic Prostate Cancer Synchronous with Male Breast Papillary Ductal Carcinoma in situ: Management Dilemma and Literature Review

2021 ◽  
pp. 784-791
Author(s):  
Harissa Husainy Hasbullah ◽  
Farah Wahida MdYusof ◽  
Amirah Hayati Ahmad ◽  
Omar Alzallal ◽  
Sharifah Emilia T. T Sharif
Keyword(s):  
Prostate Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Nipple Discharge ◽  
Breast Tumour ◽  
Prostate Adenocarcinoma ◽  
Male Breast ◽  
In Situ Management

Prostate cancer is common in men, but tumour of the male breast is rare. For these two tumours to be presented synchronously in a male patient is even rarer. The focus of this paper is the case of a 72-year-old man diagnosed with papillary ductal carcinoma in situ after he presented with a unilateral breast mass associated with nipple discharge. Imaging staging for his breast tumour and subsequent prostate biopsy found an incidental synchronous asymptomatic prostate adenocarcinoma as well as bone metastases. He denies risk factors for malignancies and refuses genetic testing. The first part of our discussion will highlight the uncommon occurrence of male breast ductal carcinoma in situ and its management controversies. The subsequent part of our discussion will focus on the association between male breast cancer and prostate cancer, and implication of this on the future treatment of these patients. More importantly, our case will illustrate the challenges in managing dual primaries that present concurrently.

scholarly journals Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy

2021 ◽  
Vol 186 (3) ◽  
pp. 617-624
Author(s):  
Kate R. Pawloski ◽  
Audree B. Tadros ◽  
Varadan Sevilimedu ◽  
Ashley Newman ◽  
Lori Gentile ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Advanced Disease ◽  
Breast Conserving Surgery ◽  
Risk Profile ◽  
High Grade ◽  
Group A ◽  
First Recurrence

Abstract Purpose Local recurrence after treatment of ductal carcinoma in situ (DCIS) with breast-conserving surgery (BCS) is more common than after mastectomy, but it is unclear if patterns of invasive recurrence vary by initial surgical therapy. Among patients with invasive recurrence after treatment for DCIS, we compared patterns of first recurrence between those originally treated with BCS vs. mastectomy. Methods From 2000 to 2016, women with an invasive recurrence occurring ≥ 6 months after initial treatment for DCIS were retrospectively identified. Clinicopathologic features and adjuvant treatment of the initial DCIS, as well as characteristics of first invasive recurrences, were compared between patients who had undergone BCS vs. mastectomy. Results 452 patients with an invasive recurrence after surgery for DCIS were identified: 367 patients (81%) had initially undergone BCS and 85 patients (19%) mastectomy. Patients originally treated with mastectomy were younger and were more likely to have had high grade, necrosis, and multifocal or multicentric DCIS (p < 0.001) compared with the BCS group. A higher proportion of invasive recurrences were local after BCS (93%; 343/367), whereas 88% (75/85) of recurrences after mastectomy were regional or distant (p < 0.001). The median time to first invasive recurrence was not different between surgical groups (BCS: 6.4 years vs. mastectomy: 5.5 years; p = 0.12). Conclusions Among women who experienced a first invasive recurrence after treatment for DCIS, those who had originally undergone mastectomy more commonly presented with advanced disease compared to those treated with BCS, likely related to the absence of the breast and the higher risk profile of their initial DCIS.

Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast

2015 ◽  
Vol 467 (1) ◽  
pp. 67-70 ◽  
Author(s):  
Verena Sailer ◽  
Christine Lüders ◽  
Walther Kuhn ◽  
Volker Pelzer ◽  
Glen Kristiansen
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
High Grade
Sign in / Sign up

Export Citation Format

Share Document